Werewolf Therapeutics Inc (HOWL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.97+2.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Werewolf is cutting costs by cutting 64% of its workers. It plans to keep cash until late 2026. The company focuses on its INDUCER T-cell platform. Recent earnings beats show some progress.
The company is still losing money and cutting many jobs. Earnings estimates are getting worse. It faces legal and listing problems. The stock price fell 67% from its high.
The market prices in a deep turnaround with ongoing losses and job cuts. Our view is cautious given worsening earnings and legal risks.
Breaks if: cash runway guidance falls short of late 2026
Breaks if: company abandons INDUCER T-cell platform in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is intact, supported by recent strong financial performance, but it faces significant risks and uncertainties.
The market seems to have priced in a challenging environment, given the company's loss-making status and high risk profile. There is an expectation for continued volatility, particularly if management guidance is cut or if economic conditions worsen.
Fundamentals may remain strong in the near term, as recent financial results have been solid. However, the company is still loss-making and has a high cash burn rate, which could impact its operations if not managed effectively.
The thesis hinges on management's ability to extend the cash runway and advance its platforms while navigating sector dynamics. Key forward scenarios include the performance of sector bellwethers and the potential impact of economic indicators on the healthcare sector.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company announced a merger with Ambros Therapeutics. This merger includes a $150 million private placement. The combined company will focus on developing neridronate for pain treatment. This gives the company enough capital to fund its clinical trials through 2029.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens beyond -$1.27 in FY26
Breaks if: workforce reduction falls below 60% by mid-2026
Continue cost reduction efforts including workforce reduction to decrease operating expenses and improve financial position.
Overall, HOWL's position is mixed, with strong recent performance but significant risks ahead. Not investment advice.